HOME › Research Insight › Acquisitions, Collaborations, and Partnerships Were the Dominant Growth Strategies Followed by Key Players in the Biochips Market
Acquisitions, Collaborations, and Partnerships Were the Dominant Growth Strategies Followed by Key Players in the Biochips Market
Abbott Laboratories (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Fluidigm Corporation (U.S.), Illumina, Inc. (U.S.), GE Healthcare (U.S.), Bio-Rad Laboratories Inc. (U.S.), Cepheid Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland) are the major players in the biochips market.
Companies operating in this market majorly focused on inorganic growth strategies, such as acquisitions, agreements, collaborations, and partnerships. Thermo Fisher Scientific is among the leaders in the biochips market, with a strong presence in different locations across the globe. The company marked its leadership position through the acquisition of Affymetrix Inc., the first company to commercialize DNA microarrays. Through this acquisition, Affymetrix added complementary products in genetic analysis, which are used in cytogenetics, genotyping, and gene expression, to the company’s life sciences portfolio. The U.S. is the major market for the company and it generates a large part of its revenue from this market; for instance, in 2015, it generated around 50.7% of its revenue from the U.S.
With more than 15 years of experience and expertise in the manufacturing and development of sequencing and array-based solutions, Illumina, Inc. is a pioneer in the field of genetic analysis. The company serves a wide base of consumers and has a strong brand image. Illumina, Inc. generated more than half of its revenue from the U.S. in 2015. The product segment accounted for 85% of the total company revenue in 2015; whereas, the services and other segment has a significant growth outlook in the near future. The company focuses on new product launches and acquisitions as its major growth strategies to sustain its position in the biochips market. For instance, in December 2015, Illumina and bioMérieux (France) launched bioMérieux EpiSeq, an innovative NGS service for epidemiological monitoring and control of healthcare-associated infections.
Biochips Market by Type (DNA Chip (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), Protein Chips), End user (Academics Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, Microfluidics) - Forecast to 2020
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India